脾腫治療薬の世界市場：2022年～2029年

当レポートでは、世界の脾腫治療薬の市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制環境、アンメットニーズ、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 脾腫治療薬市場：調査手法・調査範囲

第2章 脾腫治療薬市場：市場の定義と概要

第3章 脾腫治療薬市場：エグゼクティブサマリー

第4章 脾腫治療薬市場：市場力学

• 市場に影響を与える要因
  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析

第5章 脾腫治療薬市場：産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• アンメットニーズ

第6章 脾腫治療薬市場：COVID-19の分析

• COVID-19：市場への影響分析
• COVID-19渦中の価格ダイナミクス
• 需給スペクトル
• パンデミック時の政府の市場関連イニシアチブ
• 製造業者の戦略的イニシアチブ
• 総論

第7章 脾腫治療薬市場：治療タイプ別

• 抗生物質療法
• 化学療法
• 免疫抑制療法
• ワクチン療法
• その他

第8章 脾腫治療薬市場：流通チャネル別

• 病院薬局
• 小売薬局
• その他

第9章 脾腫治療薬市場：地域別

• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第10章 脾腫治療薬市場：競合情勢

• 主な展開・戦略
• 企業シェア分析
• 製品ベンチマーキング

第11章 脾腫治療薬市場：企業プロファイル

• Incyte Corporation
• Merck & Co., Inc.
• Novartis AG
• Sanofi
• GlaxoSmithKline plc

第12章 脾腫治療薬市場：DataM

Market Overview

The global splenomegaly therapeutics market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Splenomegaly is a condition in which the spleen grows in size or weight. Hematopoiesis and immunosurveillance are important functions of the spleen. The spleen's main functions include the removal of abnormal erythrocytes, the removal of microorganisms and antigens, and the synthesis of immunoglobulin G. (IgG).

Market Dynamics

The factors influencing the global splenomegaly therapeutics market are the increasing research and development and the growing prevalence of splenomegaly.

The increasing research and development is expected to drive the market growth in the forecast period

Splenomegaly is a condition in which the spleen grows in size or weight. Hematopoiesis and immunosurveillance are important functions of the spleen. The spleen's main functions include the removal of microorganisms and antigens and the clearance of senescent and abnormal erythrocytes and their remnants, opsonized platelets, and white blood cells. The spleen also functions as a secondary lymphoid organ, maturing and storing T and B lymphocytes, and is involved in the production of immunoglobulin G (IgG) by mature B-lymphocytes in response to interactions with T-lymphocytes. The immune system peptides properdin and tuftsin are also made in the spleen. The spleen stores about one-third of all circulating platelets. The spleen is normally found within the peritoneal cavity in the left upper quadrant, between ribs 9 and 12. The normal-sized spleen surrounds the stomach, colon, and left kidney.

Moreover, splenomegaly treatment aims to treat the underlying disease while protecting the patient from splenomegaly-related complications. Patients with splenomegaly from any cause are more likely to have their spleen rupture, so extra care must be taken to protect them from abdominal trauma. Treatment options range from avoiding abdominal injury in a young, healthy patient with splenomegaly due to infectious mononucleosis to splenectomy in a patient with hairy cell leukemia who has a massively enlarged spleen. Similarly, the prognosis is heavily influenced by the underlying disease.

Limitations associated with splenomegaly treatment are expected to hamper the market growth

There are many limitations associated with the splenomegaly treatment. For instance, limit contact sports and other activities that could rupture the spleen. A ruptured spleen can result in significant blood loss and even death. It's critical to find out what's causing the spleen to enlarge. An enlarged spleen can cause serious complications if left untreated. Treatment of the underlying cause of the enlarged spleen can usually prevent the spleen from being removed. The spleen may need to be surgically removed in some cases (splenectomy). The spleen will most likely be removed via laparoscopy rather than open surgery if surgery is required. This means that the surgery is done through a series of small incisions. The surgeon uses a laparoscope to view and remove the spleen. To avoid infection, vaccines or other medications are required.

COVID-19 Impact Analysis

The spleen plays a critical role in immune system modulation, regulating T and B cell responses to antigenic targets in the blood, and coronaviruses have been shown to prefer the spleen. In COVID-19 patients, the splenic immune function appears to be impaired, resulting in a higher mortality rate and superimposed infections. Further research could lead to a better diagnostic and therapeutic approach for SARS-CoV-2 infected patients, particularly those with pre-existing liver and spleen diseases, who appear to have a higher risk of a negative outcome. Hence, the market is expected to be positively impacted by increasing demand for impaired splenic immune function treatment.

Segment Analysis

The Antibiotic Therapy segment is expected to dominate the market growth

Splenomegaly is a condition in which the spleen grows in size. The condition is also known as spleen enlargement or enlarged spleen. The lymphatic system includes the spleen. It aids the immune system by storing white blood cells and assisting in antibody production. The doctor will need to address the underlying cause of the enlarged spleen. If an infection is the cause of an enlarged spleen, the doctor may prescribe antibiotics depending on the organism that caused the infection.

Antibiotic Therapy may help if a bacterial infection causes an enlarged spleen. Antibiotics would be useless if a virus caused an infection, as is the case with mononucleosis. Moreover, cefotaxime (adult dose of 2 g IV q8h; a pediatric dose of 25-50 mg/kg IV q6h) or ceftriaxone (adult dose of 2 g q12-24h; a pediatric dose of 50 mg/kg IV q12h) are two options for empiric antimicrobial agents.

Geographical Analysis

North America region is expected to hold the largest market share in the global splenomegaly therapeutics market

The growing prevalence of splenomegaly and increasing research and development is expected to drive the market growth in the forecast period.

Splenomegaly is a relatively uncommon condition, with an estimated prevalence of about 2% of the US population. Infectious mononucleosis, splenic infiltration with cancer cells from a hematological malignancy, and portal hypertension are the most common causes of splenomegaly in developed countries (most commonly secondary to liver disease and sarcoidosis). Hence, the splenomegaly therapeutics market in this region is expected to boost in the forecast period.

Competitive Landscape

The global splenomegaly therapeutics market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Incyte Corporation, Novartis AG, GlaxoSmithKline plc, Merck & Co., Inc., Sanofi

Incyte Corporation

Overview: Incyte is a multinational pharmaceutical corporation based in Wilmington, Delaware, and Morges, Switzerland. The company was founded in 2002 when Incyte Pharmaceuticals merged with another company.

Product Portfolio: In some patients, Jakafi (ruxolitinib) has been shown to shrink the spleen and improve the core symptoms of myelofibrosis (MF), including spleen-related symptoms. Jakafi has also been shown to help patients with MF with fatigue-related symptoms.

Why Purchase the Report?

Visualize the composition of the global splenomegaly therapeutics market segmentation by treatment type and distribution channel highlighting the key commercial assets and players.

Identify commercial opportunities in global splenomegaly therapeutics market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global splenomegaly therapeutics market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global splenomegaly therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Splenomegaly Therapeutics MarketMethodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Splenomegaly Therapeutics Market- Market Definition and Overview

3. Splenomegaly Therapeutics Market- Executive Summary

• 3.1. Market Snippet By Treatment Type
• 3.2. Market Snippet By Distribution Channel
• 3.3. Market Snippet By Region

4. Splenomegaly Therapeutics Market-Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. The increasing research and development
  • 4.1.2. Restraints:
    • 4.1.2.1. Limitations associated with splenomegaly treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Splenomegaly Therapeutics Market- Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs

6. Splenomegaly Therapeutics Market- COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Splenomegaly Therapeutics Market-By Treatment Type

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
• 7.3. Market Attractiveness Index, By Treatment Type
  • 7.3.1. Antibiotic Therapy*
    • 7.3.1.1.1. Introduction
    • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3.2. Chemotherapy
  • 7.3.3. Immunosuppressive Therapy
  • 7.3.4. Vaccine Therapy
  • 7.3.5. Others

8. Splenomegaly Therapeutics Market- By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospital Pharmacies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Retail Pharmacies
• 8.4. Other

9. Splenomegaly Therapeutics Market- By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Splenomegaly Therapeutics Market- Competitive Landscape

• 10.1. Key Developments and Strategies
• 10.2. Company Share Analysis
• 10.3. Product Benchmarking

11. Splenomegaly Therapeutics Market- Company Profiles

• 11.1. Incyte Corporation*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. Merck & Co., Inc.
• 11.3. Novartis AG
• 11.4. Sanofi
• 11.5. GlaxoSmithKline plc

LIST NOT EXHAUSTIVE

12. Splenomegaly Therapeutics Market- DataM

• 12.1. Appendix
• 12.2. About Us and Services
• 12.3. Contact Us